26. **Tonnesen P**, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. *Chest* 2006;**130**:334–42.
27. **Wagena EJ**, Knipschild PG, Huibers MJ, *et al*. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. *Arch Intern Med* 2005;**165**:2286–92.
28. **Kaper J**. Smoking cessation treatment and its reimbursement. Maastricht: University of Maastricht, 2006. <http://arno.unimaas.nl/show.cgi?fid=5377> (accessed Oct 2007).
29. **Tashkin D**, Kanner R, Bailey W, *et al*. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. *Lancet* 2001;**357**:1571–5.
30. **Brandt CJ**, Ellegaard H, Joensen M, *et al*. Effect of diagnosis of “smoker’s lung”. RYLLUNG Group. *Lancet* 1997;**349**:253.
31. **Jarvis MJ**, Powell SR, Marsh HS, *et al*. A meta-analysis of clinical studies confirms the effectiveness of bupropion SR (Zyban) in smoking cessation. Poster presentation at the 8th Annual Meeting of the Society for Research on Nicotine and Tobacco. Savannah, Georgia, 2002.
32. **Casparie AF**, van Hout BA, Simoons ML. Guidelines and costs. *Ned Tijdschr Geneesk* 1998;**142**:2075–7.
33. **Hughes J**, Stead L, Lancaster T. Antidepressants for smoking cessation. *Cochrane Database Syst Rev* 2007;(1):CD000031.
34. **Stead LF**, Perera R, Bullen C, *et al*. Nicotine replacement therapy for smoking cessation. *Cochrane Database Syst Rev* 2008;(1):CD000146.
35. **Bolin K**, Lindgren B, Willers S. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden. *Chest* 2006;**129**:651–60.
36. **Hall SM**, Lightwood JM, Humfleet GL, *et al*. Cost-effectiveness of bupropion, nortriptyline, and psychological intervention in smoking cessation. *J Behav Health Serv Res* 2005;**32**:381–92.
37. **Stapleton JA**, Lowin A, Russell MA. Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. *Lancet* 1999;**354**:210–15.
38. **Song F**, Raftery J, Aveyard P, *et al*. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. *Med Decis Making* 2002;**22**(Suppl 5):S26–37.

Lung alert

CPAP can be considered as an alternative to intubation and surfactant treatment in extremely preterm infants

In this study of 1316 infants born 24–27 weeks and 6 days gestation, extremely low weight infants were randomised to receive continuous positive airway pressure (CPAP) treatment in the delivery room or intubation and surfactant treatment <1 h after birth.

The primary outcome of death was not significantly different between treatment groups. Rates of bronchopulmonary dysplasia (supplemental oxygen requirement at 36 weeks) were also not significantly different. Secondary outcomes in this study showed that infants receiving CPAP treatment required significantly less intubation or postnatal corticosteroids for bronchopulmonary dysplasia and fewer mechanically ventilated days. Infants treated with CPAP were also more likely to be alive and off mechanical ventilation by day 7, with no other significantly different adverse outcomes between groups.

This multicentre trial strongly suggests that CPAP in the delivery room can be considered as an alternative to intubation and surfactant treatment without jeopardising extremely preterm infant outcome.

► **Finer NN**, Carlo WA, Walsh MC, *et al*; SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Early CPAP versus surfactant in extremely preterm infants. *N Engl J Med* 2010;**362**:1970–9.

J L Bacon

Correspondence to J L Bacon, East Surrey Hospital, Redhill, Surrey, UK; jenny.bacon@sash.nhs.uk

Thorax 2010;**65**:718. doi:10.1136/thx.2010.145680